Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLCN2 | P51788 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.37 |
| ▸ | CTSS | P25774 | 3/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.36 |
| ▸ | MICA | Q29983 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3902170 | 0.86 | LMNA (0.44) | LMNASLC6A9P2RX7ALDH1A1SMN1; SMN2 | |
| SCHEMBL3904027 | 0.83 | CTSS (0.56) | SLC6A9CTSSP2RX7CTSK | |
| SCHEMBL3901504 | 0.81 | LMNA (0.43) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL3240164 | 0.81 | SLC6A9 (0.45) | CLCN2LMNACASRSLC6A9CTSS | |
| SCHEMBL3906111 | 0.79 | UTS2R (0.50) | LMNASLC6A9ALDH1A1SMN1; SMN2 | |
| SCHEMBL3904017 | 0.78 | LMNA (0.40) | LMNASLC6A9ALDH1A1SMN1; SMN2 | |
| SCHEMBL3914045 | 0.78 | LMNA (0.40) | LMNASLC6A9ALDH1A1SMN1; SMN2 | |
| SCHEMBL3903962 | 0.78 | TACR1 (0.41) | — | |
| SCHEMBL3910586 | 0.78 | CRHR1 (0.46) | LMNAKLRK1MICAALDH1A1SMN1; SMN2 | |
| SCHEMBL3902029 | 0.77 | ITGB1 (0.43) | LMNASLC6A9ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838663-B1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LTD (GB) | 2009-01-21 | — | — | EP | claimed |
| US-20090270510-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270510-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270510-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1838663-B1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LTD (GB) | 2009-01-21 | — | — | EP | disclosed |
| WO-2006067417-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270510-A1 | GLYCINE TRANSPORT INHIBITORS | SLC18A2, SLC6A5, SLC1A2 | CLCN2 960/4885LMNA 4455/4885CASR 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.